Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 11/20 | 0.35 |
| ▸ | SLC2A3 | P11169 | 11/20 | 0.35 |
| ▸ | SLC2A4 | P14672 | 11/20 | 0.35 |
| ▸ | SLC2A2 | P11168 | 5/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.32 |
| ▸ | GCK | P35557 | 3/20 | 0.32 |
| ▸ | DHODH | Q02127 | 2/20 | 0.32 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.31 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.31 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12116570 | 0.97 | SLC2A1 (0.34) | SLC2A1SLC2A3SLC2A4SLC2A2KCNH2 | |
| SCHEMBL12113464 | 0.95 | SLC2A1 (0.34) | SLC2A1SLC2A3SLC2A4SLC2A2KCNH2 | |
| SCHEMBL12113378 | 0.95 | SLC2A1 (0.36) | SLC2A1SLC2A3SLC2A4SLC2A2KCNH2 | |
| SCHEMBL12117282 | 0.93 | SLC2A1 (0.35) | SLC2A1SLC2A3SLC2A4SLC2A2DHODH | |
| SCHEMBL12117077 | 0.92 | SLC2A1 (0.35) | SLC2A1SLC2A3SLC2A4SLC2A2DHODH | |
| SCHEMBL12117039 | 0.92 | DHODH (0.33) | DHODH | |
| SCHEMBL15255551 | 0.91 | DHODH (0.33) | DHODH | |
| SCHEMBL12117349 | 0.91 | RORC (0.36) | SLC2A1SLC2A3SLC2A4SLC2A2 | |
| SCHEMBL12117005 | 0.90 | SLC2A1 (0.32) | SLC2A1SLC2A3SLC2A4SLC2A2 | |
| SCHEMBL12117091 | 0.90 | SLC2A1 (0.34) | SLC2A1SLC2A3SLC2A4SLC2A2DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536202-B2 | Triazole-substituted anthranilamides as pesticides | BAYER CROPSCIENCE AG (DE) | 2013-09-17 | — | — | US | disclosed |
| US-20110275676-A1 | Triazole-substituted anthranilamides as pesticides | BAYER CROPSCIENCE AG (DE) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275676-A1 | Triazole-substituted anthranilamides as pesticides | AADAC, NAAA, ANTXR2 | SLC2A1 4803/4885SLC2A3 4685/4885SLC2A4 4817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.